[A25-03] Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2025
Project no.:
A25-03
Commission:
Commission awarded on 13.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with locally advanced, unresectable non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy
- Patients whose tumours express PD-L1 in ≥ 1% of tumour cells: added benefit not proven
- Patients whose tumours express PD-L1 in < 1% of tumour cells: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-03
| Project no. | Title | Status |
|---|---|---|
| A24-77 | Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-72 | Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-86 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-45 | Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-20 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-14 | Osimertinib - Benefit assessment according to §35a Social Code Book V | Commission completed |